{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:23:22Z","timestamp":1790011402203,"version":"4.0.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.clinthera.2021.02.002","type":"journal-article","created":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T17:09:53Z","timestamp":1615309793000},"page":"e111-e121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Effectiveness, Safety, and Adherence to Treatment of Proprotein Convertase Subtilisin\/Kexin Type 9 Inhibitors in Real Practice"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5232-1784","authenticated-orcid":false,"given":"M\u00f3nica","family":"Gayoso-Rey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaia","family":"D\u00edaz-Trastoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2221-6729","authenticated-orcid":false,"given":"Elena Yaiza","family":"Romero-Ventosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nerea","family":"Garc\u00eda-Beloso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Gonz\u00e1lez-Freire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Lorenzo-Lorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Manti\u00f1\u00e1n-Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Palmeiro-Carballeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5415-1136","authenticated-orcid":false,"given":"Marisol","family":"Bravo-Amaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda del Mar","family":"L\u00f3pez-Gil-Otero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mart\u00ednez-Reglero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Crespo-Diz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Fern\u00e1ndez-Catalina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guadalupe","family":"Pi\u00f1eiro Corrales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2021.02.002_bib1","series-title":"Pi\u00e9drola Gil. Medicina Preventiva y Salud P\u00fablica","article-title":"Epidemiolog\u00eda y prevenci\u00f3n de las enfermedades cardiovasculares","author":"Rodr\u00edguez","year":"2008"},{"key":"10.1016\/j.clinthera.2021.02.002_bib2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2021.02.002_bib4","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1080\/14740338.2019.1620730","article-title":"Safety and tolerability of injectable lipid-lowering drugs: an update of clinical data","volume":"18","author":"Strilchuck","year":"2019","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.clinthera.2021.02.002_bib5","series-title":"European Public Assessment Report. Praluent Recommended for Approval to Lower Cholesterol","year":"2015"},{"key":"10.1016\/j.clinthera.2021.02.002_bib6","author":"The European Medicines Agency"},{"key":"10.1016\/j.clinthera.2021.02.002_bib7","author":"US Food & Drug Administration"},{"key":"10.1016\/j.clinthera.2021.02.002_bib8","author":"US Food & Drug Administration"},{"key":"10.1016\/j.clinthera.2021.02.002_bib9","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"379","key":"10.1016\/j.clinthera.2021.02.002_bib10","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome","author":"Schwartz","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2021.02.002_bib11","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.atherosclerosis.2017.11.027","article-title":"PCSK9 inhibitors in clinical practice: delivering on the promise?","volume":"270","author":"Stoekenbroek","year":"2018","journal-title":"Atherosclerosis"},{"issue":"19","key":"10.1016\/j.clinthera.2021.02.002_bib12","first-page":"30276","article-title":"PCSK9 inhibitors in clinical practice: novel directions and new experiences","volume":"S1109\u20139666","author":"Rallidis","year":"2019","journal-title":"Hellenic J Cardiol"},{"key":"10.1016\/j.clinthera.2021.02.002_bib13","doi-asserted-by":"crossref","first-page":"e12439","DOI":"10.1111\/1755-5922.12439","article-title":"Lipid-lowering therapy with PCSK9-inhibitors in the real-world setting: two-year experience of a regional lipid clinic","volume":"36","author":"Zafrir","year":"2018","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.clinthera.2021.02.002_bib14","article-title":"ODYSSEY CHOICE II Investigators. Efficacy and Safety of Alirocumab 150 mg every 4 weeks in patients with hypercholesterolemia not on statin therapy: the ODYSSEY CHOICE II Study","volume":"5","author":"Stroes","year":"2016","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.clinthera.2021.02.002_bib15","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/eurheartj\/ehv028","article-title":"ODYSSEY COMBO II Investigators. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial","volume":"36","author":"Cannon","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2021.02.002_bib16","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1016\/j.jacc.2019.08.1024","article-title":"Long-term efficacy and safety of evolocumab in patients with hypercholesterolemia","volume":"74","author":"Koren","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2021.02.002_bib17","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12944-017-0416-7","article-title":"Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study","volume":"16","author":"Shah","year":"2017","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.clinthera.2021.02.002_bib18","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.3909\/ricm19S1S0002","article-title":"PCSK9 inhibitors: mechanism of action, efficacy, and safety","volume":"19","author":"Roth","year":"2018","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.clinthera.2021.02.002_bib19","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2021.02.002_bib20","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.2012.25790","article-title":"Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial","volume":"308","author":"Sullivan","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2021.02.002_bib21","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1080\/14740338.2019.1681395","article-title":"Efficacy and safety of PCSK9 monoclonal antibodies","author":"Iqbal","year":"2019","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.clinthera.2021.02.002_bib22","first-page":"265","article-title":"Real-world use of PCSK9 inhibitors: a single-center experience","volume":"47","author":"Sarsam","year":"2019","journal-title":"J\u00a0Int Med Res"},{"key":"10.1016\/j.clinthera.2021.02.002_bib23","doi-asserted-by":"crossref","first-page":"32","DOI":"10.5603\/CJ.a2017.0137","article-title":"Lipid-lowering therapy with PCSK9-inhibitors in the management of cardiovascular high-risk patients: effectiveness, therapy adherence and safety in a real-world cohort","volume":"25","author":"Saborowsky","year":"2018","journal-title":"Cardiol J"},{"key":"10.1016\/j.clinthera.2021.02.002_bib24","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/03007995.2018.1532885","article-title":"Real world treatment patterns of PCSK9 inhibitors among patients with dyslipidemia in Germany, Spain, and United Kingdom","volume":"35","author":"Tai","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2021.02.002_bib25","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.5554","article-title":"Association of a combined measure of adherence and treatment intensity with cardiovascular outcomes in patients with atherosclerosis or other cardiovascular risk factors treated with statins and\/or ezetimibe","volume":"1","author":"Khunti","year":"2018","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clinthera.2021.02.002_bib26","doi-asserted-by":"crossref","first-page":"378","DOI":"10.4321\/S1886-36552014000200002","article-title":"Assessing the adherence to and the therapeutic effectiveness of hypolipidemic agents in a population of patients in Brazil: a retrospective cohort study","volume":"12","author":"Cunico","year":"2014","journal-title":"Pharm Pract (Granada)"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821000990?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821000990?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:54:08Z","timestamp":1758963248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291821000990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0149291821000990"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.02.002","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness, Safety, and Adherence to Treatment of Proprotein Convertase Subtilisin\/Kexin Type 9 Inhibitors in Real Practice","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}